GSK
NICE refuses cancer drugs Arzerra, Torisel and Levact
October 27, 2010Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs
NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
GSK cleared of unethical practices by PMCPA
October 22, 2010Medical Communications ABPI, ABPI Code of Practice, Avamys, GSK, GlaxoSmithKline, PMCPA, Rupafin, Seretide
GlaxoSmithKline has been found guilty of two transgressions of the ABPI Code of Practice in a case centring on the …
Revenue slump for GSK as Avandia sales stall
October 22, 2010Sales and Marketing Avandia, GSK, GlaxoSmithKline, UK science budget, patent box, pharma's 2010 results, pharma's Q3 results
GlaxoSmithKline has posted a third quarter loss after sales of its troubled diabetes drug Avandia and pandemic influenza products fell. …
GSK’s leukaemia drug rejected by NICE
September 16, 2010Sales and Marketing Arzerra, GSK, NHS, NICE
GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …
Avandia letter misleading, FDA tells Glaxo
August 24, 2010Sales and Marketing Avandia, GSK
GlaxoSmithKline’s travails over controversial diabetes drug Avandia show no sign of abating as members of a key regulatory panel accused …
Pharma provides aid for Pakistan
August 24, 2010Sales and Marketing GSK, NGO, Novartis, Pakistan, disaster, pharma, relief
The pharma industry is providing donations to help those affected by the mass flooding across Pakistan. As many as 20 …
GSK shingles vaccine enters late stage trials
August 23, 2010Research and Development, Sales and Marketing GSK, Vaccine, shingles
GlaxoSmithKline has started enrollment for phase III trials for its herpes zoster vaccine for the prevention of shingles. The trials …
Benlysta to be fast-tracked by FDA
August 20, 2010Sales and Marketing Benlysta, GSK, HGS, Lupus
New lupus drug Benlysta has been given priority review status by the FDA.Benlysta (belimumab) has been developed by Human Genome …
Regenerative medicine: small steps towards the great leap forward
August 16, 2010Research and Development GSK, Pfizer, Stem cells, regenerative medicine
Susan Aldridge reports on what some of the leading pharma companies are doing in the regenerative medicine and stem cells …
German patent setback for GlaxoSmithKline’s Seretide
May 21, 2010Sales and Marketing GSK, Germany, Seretide
A Munich court has ruled GlaxoSmithKline’s combination patent for its asthma and COPD treatment Seretide is not valid. The Federal …
FDA backs rotavirus vaccine despite contamination
May 13, 2010Sales and Marketing GSK, Rotavirus, Vaccine, drug safety, rotarix
FDA advisors have recommended two rotavirus vaccines licensed in the US should continue to be used, despite contamination with a …
GSK appoints Patrick Vallance
May 12, 2010Research and Development GSK, appointment, research and development
Patrick Vallance has been appointed as senior vice president, medicines discovery and development at GlaxoSmithKline, and as a member of …
GSK bolsters presence in South Korea
May 11, 2010Sales and Marketing Dong-A, GSK, Korea, em
GlaxoSmithKline has followed through with plans to expand into emerging markets by striking a co-marketing deal with South Korea’s largest …
Asia and emerging markets boost GSK results
April 28, 2010Sales and Marketing GSK
Asia and emerging markets boost GlaxoSmithKline results GlaxoSmithKline has seen a jump in pharma sales due to major growth in …
Secondary endpoints failure take shine off Benlysta
April 21, 2010Sales and Marketing GSK, HGS, Lupus
GlaxoSmithKline’s lupus treatment has failed to reach a statistically significant secondary endpoint in the second of two phase III trials. …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
